Infinity Pharmaceuti (INFI) 1.40 $INFI
Infinity Regains Duvelisib Rights, Announces Restructuring
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 10:08AM CDT
Infinity Pharmaceuticals (INFI) regained rights to develop and commercialize duvelisib; the company plans to eliminate 100 positions across the organization.
PFE: 36.12 (+0.35), ABBV: 64.16 (+0.73), INFI: 1.40 (+0.08), BMY: 75.28 (+1.20)
Infinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration
PR Newswire - Tue Jun 28, 5:55AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that AbbVie Inc. has exercised its right to end its collaboration with Infinity to develop and commercialize duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The companies had been in discussions regarding a potential restructuring of the partnership but were unable to find a mutually attractive financial structure for continuation of the collaboration. With the termination of this agreement, Infinity has regained worldwide rights to duvelisib and neither Infinity nor AbbVie have future financial obligations to the other party.
INFI: 1.40 (+0.08)
Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics
PR Newswire - Thu Jun 23, 7:20AM CDT
On Wednesday, June 22, 2016, the NASDAQ Composite ended the trading session at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% lower to finish at 17,780.83; and the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Nektar Therapeutics (NASDAQ: NKTR), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and BIND Therapeutics Inc. (NASDAQ: BIND). Learn more about these stocks by accessing their free trade alerts at:
BIND: 0.56 (+0.01), ARLZ: 3.61 (+0.05), INFI: 1.40 (+0.08), NKTR: 14.92 (+0.62)
Lifshitz & Miller Law Firm Announces Investigation of CBL & Associates Properties, Inc., Eagle Pharmaceuticals, Inc., HCP, Inc., Immunomedics, Inc., Infinity Pharmaceuticals Inc., Neovasc, Inc., and Unilife Corporation
PR Newswire - Fri Jun 17, 6:09PM CDT
CBL & Associates Properties, Inc. (CBL)Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the CBL board. Specifically, on May 24, 2016, the Wall Street Journal reported investigations concerning CBL officials falsifying information on financial statements to banks when applying for financial arrangements.
IMMU: 2.48 (+0.11), HCP: 35.94 (+1.06), UNIS: 3.48 (+0.07), CBL: 10.08 (+0.23), INFI: 1.40 (+0.08), EGRX: 42.78 (-0.36), NVCN: 0.49 (-0.01)
Downgrade Alert for Infinity Pharmaceuticals (INFI)
Comtex SmarTrend(R) - Thu Jun 16, 4:01AM CDT
Infinity Pharmaceuticals (NASDAQ:INFI) was downgraded from Outperform to Sector Perform at RBC Capital today. The stock closed yesterday at $1.50 on volume of 11.0 million shares, above average daily volume of 504,000. Infinity Pharmaceuticals, Inc. researches and develops cancer drugs. The Company uses small molecule drug technologies in the development of its products.
INFI: 1.40 (+0.08)
Infinity (INFI) at 52-Week Low on Disappointing Duvelisib Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:45AM CDT
Infinity (INFI) announced disappointing results from the phase II DYNAMO study on duvelisib for the treatment of patients with refractory indolent non-Hodgkin lymphoma.
PFE: 36.12 (+0.35), ABBV: 64.16 (+0.73), INFI: 1.40 (+0.08), BMY: 75.28 (+1.20)
Upgrade Alert for Infinity Pharmaceuticals (INFI)
Comtex SmarTrend(R) - Wed Jun 15, 3:10AM CDT
Infinity Pharmaceuticals (NASDAQ:INFI) was upgraded from Underperform to Neutral at Wedbush today. The stock closed yesterday at $1.36 on volume of 19.7 million shares, above average daily volume of 504,000. Infinity Pharmaceuticals, Inc. researches and develops cancer drugs. The Company uses small molecule drug technologies in the development of its products.
INFI: 1.40 (+0.08)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Infinity Pharmaceuticals, Inc.
BusinessWire - Tue Jun 14, 12:39PM CDT
Levi & Korsinsky announces it has commenced an investigation of Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company"
(NASDAQ: INFI) concerning possible violations of federal securities laws.
INFI: 1.40 (+0.08)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Infinity Pharmaceuticals Inc. - INFI
PR Newswire - Tue Jun 14, 11:23AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Infinity Pharmaceuticals Inc. ("Infinity" or the Company) (NASDAQ: INFI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
INFI: 1.40 (+0.08)
Hot Stock: Infinity Pharmaceuticals, Shares Drop 68.7% (INFI)
Comtex SmarTrend(R) - Tue Jun 14, 8:50AM CDT
Infinity Pharmaceuticals (NASDAQ:INFI) is one of today's worst performing low-priced stocks, down 68.7% to $1.38 on 8.2x average daily volume. Infinity Pharmaceuticals has traded 4.1 million shares thus far today, vs. average volume of 504,000 shares per day. The stock has underperformed the Dow (-68.7% to the Dow's -0.1%) and underperformed the S&P 500 (-68.7% to the S&P's -0.0%) during today's trading.
INFI: 1.40 (+0.08)
Infinity Reports Topline Results From DYNAMO(TM), A Phase 2 Monotherapy Study Of Investigational Molecule Duvelisib In Refractory Indolent Non-Hodgkin Lymphoma
PR Newswire - Tue Jun 14, 4:45AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that DYNAMO(TM), a registration-focused Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with refractory indolent non-Hodgkin lymphoma (iNHL) met its primary endpoint of overall response rate. In the study, duvelisib demonstrated an overall response rate (ORR) of 46 percent, all of which were partial responses, among 129 patients with iNHL. The majority of reported side effects were reversible and clinically manageable.
INFI: 1.40 (+0.08)
Infinity Announces Launch Of Disease Awareness Campaign For Hematologic Malignancies
PR Newswire - Wed Jun 01, 7:05AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the launch of a mechanism of disease (MOD) awareness initiative designed to educate community and academic hematologists/oncologists about the role of the tumor microenvironment in patients with certain hematologic malignancies, or blood cancers. With more research emerging about the role of the tumor microenvironment in hematologic malignancies, Infinity developed this campaign to contribute to the emerging knowledge of this scientific concept and its clinical relevance. The initiative will be showcased in the Infinity booth (#22415) at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from June 3 - June 7, 2016. Additional information and resources on the tumor microenvironment are available on a newly launched website: www.manipulatedTME.com.
INFI: 1.40 (+0.08)
Infinity To Participate In Three June Investor Conferences
PR Newswire - Tue May 31, 3:05PM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that management will present at the following investor conferences:
INFI: 1.40 (+0.08)
Are These Biotech Stocks Prescribed for Investors' Portfolio? - Anacor Pharma, Athersys, Aralez Pharma and Infinity Pharma
PR Newswire - Fri May 20, 7:10AM CDT
The Biotech arena remains under immense pressure, yet many veteran investors believe that the industry is not far from recovering. There are great companies in this space, and today ActiveWallSt.com featured the following four equities: Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Athersys Inc. (NASDAQ: ATHX), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Sign up for your free trading alerts on these biotech stocks at:
INFI: 1.40 (+0.08), ARLZ: 3.61 (+0.05), ANAC: 99.06 (-0.14), ATHX: 2.29 (+0.05)
Infinity Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming EHA And ASCO Meetings
PR Newswire - Thu May 19, 7:00AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that new data will be presented for duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, at the 21st Congress of the European Hematology Association (EHA) taking place from June 9 - 12, 2016, in Copenhagen. At the meeting, preliminary data from CONTEMPO, a Phase 1b/2 study evaluating duvelisib in combination with rituximab or obinutuzmab in treatment-naïve follicular lymphoma patients, will be presented in a poster session. Duvelisib is the only dual inhibitor of PI3K-delta,gamma in Phase 3 clinical development and is in registration-focused studies in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) and relapsed/refractory chronic lymphocytic leukemia (CLL). Infinity and AbbVie are jointly developing duvelisib in oncology.
INFI: 1.40 (+0.08)
Infinity Provides Company Update And Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:05PM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2016 financial results and ongoing progress with its pipeline, including duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, and IPI-549, an immuno-oncology development candidate that selectively inhibits PI3K-gamma.
INFI: 1.40 (+0.08)
Infinity Regains Duvelisib Rights, Announces Restructuring
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 10:08AM CDT
Infinity Pharmaceuticals (INFI) regained rights to develop and commercialize duvelisib; the company plans to eliminate 100 positions across the organization.
PFE: 36.12 (+0.35), ABBV: 64.16 (+0.73), INFI: 1.40 (+0.08), BMY: 75.28 (+1.20)
Infinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration
PR Newswire - Tue Jun 28, 5:55AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that AbbVie Inc. has exercised its right to end its collaboration with Infinity to develop and commercialize duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The companies had been in discussions regarding a potential restructuring of the partnership but were unable to find a mutually attractive financial structure for continuation of the collaboration. With the termination of this agreement, Infinity has regained worldwide rights to duvelisib and neither Infinity nor AbbVie have future financial obligations to the other party.
INFI: 1.40 (+0.08)
Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics
PR Newswire - Thu Jun 23, 7:20AM CDT
On Wednesday, June 22, 2016, the NASDAQ Composite ended the trading session at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% lower to finish at 17,780.83; and the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Nektar Therapeutics (NASDAQ: NKTR), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and BIND Therapeutics Inc. (NASDAQ: BIND). Learn more about these stocks by accessing their free trade alerts at:
BIND: 0.56 (+0.01), ARLZ: 3.61 (+0.05), INFI: 1.40 (+0.08), NKTR: 14.92 (+0.62)
Lifshitz & Miller Law Firm Announces Investigation of CBL & Associates Properties, Inc., Eagle Pharmaceuticals, Inc., HCP, Inc., Immunomedics, Inc., Infinity Pharmaceuticals Inc., Neovasc, Inc., and Unilife Corporation
PR Newswire - Fri Jun 17, 6:09PM CDT
CBL & Associates Properties, Inc. (CBL)Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the CBL board. Specifically, on May 24, 2016, the Wall Street Journal reported investigations concerning CBL officials falsifying information on financial statements to banks when applying for financial arrangements.
IMMU: 2.48 (+0.11), HCP: 35.94 (+1.06), UNIS: 3.48 (+0.07), CBL: 10.08 (+0.23), INFI: 1.40 (+0.08), EGRX: 42.78 (-0.36), NVCN: 0.49 (-0.01)
Downgrade Alert for Infinity Pharmaceuticals (INFI)
Comtex SmarTrend(R) - Thu Jun 16, 4:01AM CDT
Infinity Pharmaceuticals (NASDAQ:INFI) was downgraded from Outperform to Sector Perform at RBC Capital today. The stock closed yesterday at $1.50 on volume of 11.0 million shares, above average daily volume of 504,000. Infinity Pharmaceuticals, Inc. researches and develops cancer drugs. The Company uses small molecule drug technologies in the development of its products.
INFI: 1.40 (+0.08)
Infinity (INFI) at 52-Week Low on Disappointing Duvelisib Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:45AM CDT
Infinity (INFI) announced disappointing results from the phase II DYNAMO study on duvelisib for the treatment of patients with refractory indolent non-Hodgkin lymphoma.
PFE: 36.12 (+0.35), ABBV: 64.16 (+0.73), INFI: 1.40 (+0.08), BMY: 75.28 (+1.20)
Upgrade Alert for Infinity Pharmaceuticals (INFI)
Comtex SmarTrend(R) - Wed Jun 15, 3:10AM CDT
Infinity Pharmaceuticals (NASDAQ:INFI) was upgraded from Underperform to Neutral at Wedbush today. The stock closed yesterday at $1.36 on volume of 19.7 million shares, above average daily volume of 504,000. Infinity Pharmaceuticals, Inc. researches and develops cancer drugs. The Company uses small molecule drug technologies in the development of its products.
INFI: 1.40 (+0.08)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Infinity Pharmaceuticals, Inc.
BusinessWire - Tue Jun 14, 12:39PM CDT
Levi & Korsinsky announces it has commenced an investigation of Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company"
(NASDAQ: INFI) concerning possible violations of federal securities laws. INFI: 1.40 (+0.08)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Infinity Pharmaceuticals Inc. - INFI
PR Newswire - Tue Jun 14, 11:23AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Infinity Pharmaceuticals Inc. ("Infinity" or the Company) (NASDAQ: INFI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
INFI: 1.40 (+0.08)
Hot Stock: Infinity Pharmaceuticals, Shares Drop 68.7% (INFI)
Comtex SmarTrend(R) - Tue Jun 14, 8:50AM CDT
Infinity Pharmaceuticals (NASDAQ:INFI) is one of today's worst performing low-priced stocks, down 68.7% to $1.38 on 8.2x average daily volume. Infinity Pharmaceuticals has traded 4.1 million shares thus far today, vs. average volume of 504,000 shares per day. The stock has underperformed the Dow (-68.7% to the Dow's -0.1%) and underperformed the S&P 500 (-68.7% to the S&P's -0.0%) during today's trading.
INFI: 1.40 (+0.08)
Infinity Reports Topline Results From DYNAMO(TM), A Phase 2 Monotherapy Study Of Investigational Molecule Duvelisib In Refractory Indolent Non-Hodgkin Lymphoma
PR Newswire - Tue Jun 14, 4:45AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that DYNAMO(TM), a registration-focused Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with refractory indolent non-Hodgkin lymphoma (iNHL) met its primary endpoint of overall response rate. In the study, duvelisib demonstrated an overall response rate (ORR) of 46 percent, all of which were partial responses, among 129 patients with iNHL. The majority of reported side effects were reversible and clinically manageable.
INFI: 1.40 (+0.08)
Infinity Announces Launch Of Disease Awareness Campaign For Hematologic Malignancies
PR Newswire - Wed Jun 01, 7:05AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the launch of a mechanism of disease (MOD) awareness initiative designed to educate community and academic hematologists/oncologists about the role of the tumor microenvironment in patients with certain hematologic malignancies, or blood cancers. With more research emerging about the role of the tumor microenvironment in hematologic malignancies, Infinity developed this campaign to contribute to the emerging knowledge of this scientific concept and its clinical relevance. The initiative will be showcased in the Infinity booth (#22415) at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from June 3 - June 7, 2016. Additional information and resources on the tumor microenvironment are available on a newly launched website: www.manipulatedTME.com.
INFI: 1.40 (+0.08)
Infinity To Participate In Three June Investor Conferences
PR Newswire - Tue May 31, 3:05PM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that management will present at the following investor conferences:
INFI: 1.40 (+0.08)
Are These Biotech Stocks Prescribed for Investors' Portfolio? - Anacor Pharma, Athersys, Aralez Pharma and Infinity Pharma
PR Newswire - Fri May 20, 7:10AM CDT
The Biotech arena remains under immense pressure, yet many veteran investors believe that the industry is not far from recovering. There are great companies in this space, and today ActiveWallSt.com featured the following four equities: Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Athersys Inc. (NASDAQ: ATHX), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Sign up for your free trading alerts on these biotech stocks at:
INFI: 1.40 (+0.08), ARLZ: 3.61 (+0.05), ANAC: 99.06 (-0.14), ATHX: 2.29 (+0.05)
Infinity Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming EHA And ASCO Meetings
PR Newswire - Thu May 19, 7:00AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that new data will be presented for duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, at the 21st Congress of the European Hematology Association (EHA) taking place from June 9 - 12, 2016, in Copenhagen. At the meeting, preliminary data from CONTEMPO, a Phase 1b/2 study evaluating duvelisib in combination with rituximab or obinutuzmab in treatment-naïve follicular lymphoma patients, will be presented in a poster session. Duvelisib is the only dual inhibitor of PI3K-delta,gamma in Phase 3 clinical development and is in registration-focused studies in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) and relapsed/refractory chronic lymphocytic leukemia (CLL). Infinity and AbbVie are jointly developing duvelisib in oncology.
INFI: 1.40 (+0.08)
Infinity Provides Company Update And Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:05PM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2016 financial results and ongoing progress with its pipeline, including duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, and IPI-549, an immuno-oncology development candidate that selectively inhibits PI3K-gamma.
INFI: 1.40 (+0.08)
